Companies: 10,795·Total market cap: $144.5T
Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc

INDVNASDAQHealthcare● Active
$37.89
+$0.28(+0.73%)
Market Cap$4.7B
P/E Ratio—
52W High$41
52W Low$13.42
SEC Filings

Indivior Pharmaceuticals Inc (INDV) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001625297 · INDV · NASDAQ · as of Jun 8, 2026

Filing snapshot

518
Total Filings
8-K
Latest Form
2026-05-15
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001625297 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001628280-26-012237
Primary Document
indv-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001625297 · Accession 0001628280-26-012237

Latest Key Filings

10-QQuarterly Report
10-Q
2026-04-30
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-15Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-13
View
8-KCurrent Report
8-K
2026-05-04
View
10-QQuarterly Report
10-Q
2026-04-30
View
8-KCurrent Report
8-K
2026-04-30
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-28
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-27
View
ARSARS
ARS
2026-03-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-03-27
View
DEF 14AProxy Statement
DEF 14A
2026-03-27
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-03-23
View
8-KCurrent Report
8-K
2026-03-17
View
8-KCurrent Report
8-K
2026-03-13
View
8-KCurrent Report
8-K
2026-03-12
View
Showing 1–15 of 478 filingsForm 4 / 144 hidden· 518 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001625297  |  Exchange: NASDAQ · Healthcare

Indivior Pharmaceuticals Inc (NASDAQ: INDV) has submitted 518 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001625297, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Indivior Pharmaceuticals Inc's most comprehensive regulatory disclosure. The most recent Indivior Pharmaceuticals Inc 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical INDV 10-K annual reports are available from 2014 through 2026.

Investors researching Indivior Pharmaceuticals Inc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
LNTH SEC Filings →PRAX SEC Filings →HNGE SEC Filings →AMRX SEC Filings →ACAD SEC Filings →CRNX SEC Filings →VKTX SEC Filings →OPCH SEC Filings →
→ INDV Financials→ INDV Earnings→ INDV Insider Trades

Frequently Asked Questions

INDV SEC Filings · 8 questions

Indivior Pharmaceuticals Inc (INDV) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 518 filings and access original documents at no cost. Indivior Pharmaceuticals Inc's CIK is 0001625297.

INDV SEC filingsIndivior Pharmaceuticals Inc SEC documentsfind INDV 10-K